Variables | All patients (n = 42) | Responders (n = 29, 69%) | Non-Responders (n = 13, 31%) | P Value |
---|---|---|---|---|
Demographic data | ||||
Age, years | 66 ± 12 | 66 ± 11 | 66 ± 15 | 0.83 |
Male, n (%) | 30 (68) | 19 (65) | 10 (77) | 0.45 |
CAD, n (%) | 30 (68) | 18 (62) | 11 (85) | 0.13 |
Clinical data | ||||
QRS duration, ms | 159 ± 28 | 162 ± 27 | 155 ± 30 | 0.51 |
LBBB, n (%) | 27 (61) | 19 (65) | 6 (46) | 0.24 |
RBBB, n (%) | 2 (4.5) | 2 (7) | 0 (0) | ... |
IVCD, n (%) | 8 (18) | 3 (10) | 5 (38) | 0.04 |
PR, ms | 180 ± 40 | 172 ± 32 | 195 ± 51 | 0.08 |
Pre-CRT pacing, n (%) | 7 (16) | 5 (17) | 2 (15) | 0.88 |
NYHA III/IV, n (%) | 31 (70)/13 (30) | 22 (76)/7 (24) | 7 (54)/6 (46) | 0.16 |
Medication | ||||
Diuretic, n (%) | 41 (93) | 27 (93) | 12 (92) | 0.93 |
β-Blockers, n (%) | 41 (93) | 26 (90) | 13 (100) | 0.13 |
ACEi, n (%) | 31 (70) | 20 (69) | 10 (77) | 0.59 |
AR Blockers, n (%) | 13 (30) | 9 (32) | 3 (23) | 0.55 |
Digoxin, n (%) | 11 (25) | 5 (17) | 6 (46) | 0.06 |
Spironolactone, n (%) | 26 (59) | 15 (52) | 10 (77) | 0.12 |